Protalex (PRTX) 10-K 5 Aug 14 2014 FY Annual report Financial data

Document_And_Entity_Informatio

Document And Entity Information (USD $)	12 Months Ended
In Millions, except Share data, unless otherwise specified	31-May-14	Aug. 04, 2014	Nov. 30, 2013
Document Information [Line Items]	'	'	'
Document Type	'10-K	'	'
Amendment Flag	'false	'	'
Document Period End Date	31-May-14	'	'
Document Fiscal Year Focus	'2014	'	'
Document Fiscal Period Focus	'FY	'	'
Entity Registrant Name	'PROTALEX INC	'	'
Entity Central Index Key	'0001099215	'	'
Current Fiscal Year End Date	'--05-31	'	'
Entity Well-known Seasoned Issuer	'No	'	'
Entity Voluntary Filers	'No	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Filer Category	'Smaller Reporting Company	'	'
Entity Public Float	'	'	$48.90
Trading Symbol	'PRTX	'	'
Entity Common Stock, Shares Outstanding	'	28,767,582	'

BALANCE_SHEETS

BALANCE SHEETS (USD $)	31-May-14	31-May-13
CURRENT ASSETS:	'	'
Cash and cash equivalents	$1,614,758	$2,457,046
Prepaid expenses	45,327	42,320
Total current assets	1,660,085	2,499,366
OTHER ASSETS:	'	'
Intellectual technology property, net of accumulated amortization of $14,088 and $13,068 as of May 31, 2014 and May 31, 2013, respectively	5,447	6,467
Total other assets	5,447	6,467
Total Assets	1,665,532	2,505,833
CURRENT LIABILITIES:	'	'
Accounts payable	412,718	671,738
Accrued expenses	40,135	62,517
Current portion - long term debt- related party	0	4,210,833
Total current liabilities	452,853	4,945,088
LONG TERM LIABILITIES:	'	'
Senior Secured Note - related party	9,000,000	6,000,000
Senior Secured Note Accrued Interest - related party	397,168	57,616
Total liabilities	9,850,021	11,002,704
STOCKHOLDERS' EQUITY (DEFICIT)	'	'
Preferred stock, par value $0.00001, 1,000,000 shares authorized; none issued and outstanding	0	0
Common stock, par value $0.00001, 100,000,000 shares authorized; 28,767,582 and 18,926,615 shares issued and outstanding, respectively	288	189
Additional paid in capital	65,402,505	53,237,993
Accumulated deficit	-73,587,282	-61,735,053
Total stockholders' equity (deficit)	-8,184,489	-8,496,871
Total liabilities and stockholders' equity (deficit)	$1,665,532	$2,505,833

BALANCE_SHEETS_Parenthetical

BALANCE SHEETS (Parenthetical) (USD $)	31-May-14	31-May-13
Intellectual technology property, accumulated amortization	$14,088	$13,068
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	28,767,582	18,926,615
Common stock, shares outstanding	28,767,582	18,926,615

STATEMENTS_OF_OPERATIONS

STATEMENTS OF OPERATIONS (USD $)	12 Months Ended
	31-May-14	31-May-13
Revenues	$0	$0
Operating Expenses	'	'
Research and development	3,232,321	3,833,401
Administrative	7,750,587	1,345,152
Professional fees	584,585	440,751
Depreciation and amortization	1,020	1,020
Operating loss	-11,568,513	-5,620,324
Other income (expense)	'	'
Interest income	4	3,956
Interest expense	-283,720	-663,866
Loss before income taxes	-11,852,229	-6,280,234
Provision for income taxes	0	0
Net loss	($11,852,229)	($6,280,234)
Weighted average number of common shares outstanding	26,222,563	18,926,615
Loss per common share - basic and diluted	($0.45)	($0.33)

STATEMENT_OF_CHANGES_IN_STOCKH

STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) (USD $)

Total

Issuance During Period 1st

Issuance During Period 2nd

Common Stock

Common Stock

Common Stock

Additional Paid in Capital

Additional Paid in Capital

Additional Paid in Capital

Accumulated Deficit

Accumulated Deficit

Accumulated Deficit

Issuance During Period 1st

Issuance During Period 2nd

Issuance During Period 1st

Issuance During Period 2nd

Issuance During Period 1st

Issuance During Period 2nd

Beginning Balance at May. 31, 2012

($3,123,614)

'

'

$189

'

'

$52,331,016

'

'

($55,454,819)

'

'

Beginning Balance (in shares) at May. 31, 2012

'

'

'

18,926,683

'

'

'

'

'

'

'

'

Shared-based Expense (in shares)

'

'

'

0

'

'

'

'

'

'

'

'

Shared-based Expense

906,977

'

'

0

'

'

906,977

'

'

0

'

'

Net loss

-6,280,234

'

'

0

'

'

0

'

'

-6,280,234

'

'

Ending balance at May. 31, 2013

-8,496,871

'

'

189

'

'

53,237,993

'

'

-61,735,053

'

'

Ending balance (in shares) at May. 31, 2013

'

'

'

18,926,683

'

'

'

'

'

'

'

'

Shared-based Expense (in shares)

'

'

'

0

'

'

'

'

'

'

'

'

Shared-based Expense

7,228,008

'

'

0

'

'

7,228,008

'

'

0

'

'

Common stock issued (in shares)

'

'

'

'

9,369,565

471,334

'

'

'

'

'

'

Common stock issued

'

2,155,000

2,781,603

'

94

5

'

2,154,906

2,781,598

'

0

0

Net loss

-11,852,229

'

'

0

'

'

0

'

'

-11,852,229

'

'

Ending balance at May. 31, 2014

($8,184,489)

'

'

$288

'

'

$65,402,505

'

'

($73,587,282)

'

'

Ending balance (in shares) at May. 31, 2014

'

'

'

28,767,582

'

'

'

'

'

'

'

'

STATEMENT_OF_CHANGES_IN_STOCKH1

STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical)	12 Months Ended
	31-May-14
Issuance During Period 1st	'
Common Stock issued, issuance date	27-Aug-13
Issuance During Period 2nd	'
Common Stock issued, issuance date	23-Jan-14

STATEMENTS_OF_CASH_FLOWS

STATEMENTS OF CASH FLOWS (USD $)	12 Months Ended
	31-May-14	31-May-13
CASH FLOWS FROM OPERATING ACTIVITIES:	'	'
Net loss	($11,852,229)	($6,280,234)
Adjustments to reconcile net loss to net cash and cash equivalents used in operating activities	'	'
(Gain) on disposal of equipment, net	0	0
Depreciation and amortization	1,020	1,020
Equity based expense	7,228,008	906,977
(Increase)/decrease in:	'	'
Prepaid expenses and deposits	-3,008	360
Increase/(decrease) in:	'	'
Accounts payable and accrued expenses	-281,402	638,528
Accrued interest payable	283,720	0
Net cash and cash equivalents used in operating activities	-4,623,891	-4,733,349
CASH FLOWS FROM FINANCING ACTIVITIES:	'	'
Proceeds from stock issuance, including options and warrants exercised	2,781,603	0
Issuance of note payable to individuals	1,000,000	7,000,000
Net cash and cash equivalents provided by financing activities	3,781,603	7,000,000
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS	-842,288	2,266,651
Cash and cash equivalents, beginning	2,457,046	190,395
Cash and cash equivalents, ending	1,614,758	2,457,046
SUPPLEMENTAL SCHEDULE OF CASH FLOW INFORMATION:	'	'
Interest paid	0	0
Taxes paid	0	0
NONCASH FINANCING ACTIVITIES:	'	'
Conversion of debt to equity	$2,155,000	$0

ORGANIZATION_AND_BUSINESS_ACTI

ORGANIZATION AND BUSINESS ACTIVITIES	12 Months Ended
	31-May-14
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
ORGANIZATION AND BUSINESS ACTIVITIES	'
		1	ORGANIZATION AND BUSINESS ACTIVITIES
	The Company is focused on the development of a class of biopharmaceutical drugs for treating autoimmune inflammatory diseases including rheumatoid arthritis (RA). Its lead product, PRTX-100, is a formulation of highly-purified form of staphylococcal protein A, which is an immune modulating protein produced by bacteria.
	The Company maintains an administrative office in Florham Park, New Jersey and currently outsources all of its product development and regulatory activities, including clinical trial activities, manufacturing and laboratory operations to third-party contract research organizations and facilities.
	In April 2009, the Company ceased all operations and terminated all employees in light of insufficient funds to continue its clinical trials and related product development. The Company’s business was dormant until new management took control of its operations in November 2009 following the change in control transaction more fully described below. The Company is currently actively pursuing the commercial development of PRTX-100 for the treatment of RA.
	On December 8, 2010, the Company effected a reverse stock split of the outstanding shares of its common stock, with par value of $0.00001 per share (“Common Stock”), on the basis of one share of Common Stock for each five shares of Common Stock outstanding. Unless otherwise noted, all references in these financial statements and notes to financial statements to number of shares, price per share and weighted average number of shares outstanding of Common Stock prior to this reverse stock split have been adjusted to reflect the reverse stock split on a retroactive basis.
	PRTX-100 has demonstrated effectiveness in animal models of autoimmune diseases as well as demonstrated activity on cultured human immune cells at very low concentrations, although the effectiveness of PRTX-100 shown in pre-clinical studies using animal models may not be predictive of the results that the Company would see in future human clinical trials. The Company does not anticipate generating operating revenue for the foreseeable future and does not currently have any products that are marketable.
	The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, which contemplate continuation of the Company as a going concern. The ability of the Company to continue as a going concern is dependent upon developing products that are regulatory approved and market accepted. There is no assurance that these plans will be realized in whole or in part. The financial statements do not include any adjustments that might result from the outcome of these uncertainties.

CHANGE_OF_OWNERSHIP_TRANSACTIO

CHANGE OF OWNERSHIP TRANSACTION	12 Months Ended
	31-May-14
Working Capital Information [Abstract]	'
CHANGE OF OWNERSHIP TRANSACTION	'
	2. CHANGE OF OWNERSHIP TRANSACTION
	On November 11, 2009 (the “Effective Date”), the Company consummated a financing transaction (the “Financing”) in which it raised $3,000,000 of working capital pursuant to a Securities Purchase Agreement (the “Purchase Agreement”) with Niobe Ventures, LLC, a Delaware limited liability company (“Niobe”). Pursuant to the Purchase Agreement, the Company issued to Niobe (i) 8,695,652 restricted shares of Common Stock at a purchase price of $0.23 per share (or $2 million in the aggregate) and (ii) a senior secured convertible promissory note in the principal amount of $1 million convertible into shares of Common Stock at an initial conversion price equal to $0.23 per share (the “$1 Million Secured Note”). On February 11, 2011, Niobe converted the $1 Million Secured Note, including $37,500 of accrued interest thereon, into 4,510,870 shares of Common Stock.
	As contemplated by the Purchase Agreement, all of the Company’s executive officers and all of the members of its Board of Directors (the “Board”) prior to the closing of the Financing, with the exception of Frank M. Dougherty, resigned effective concurrently with the closing of the Financing.  Mr. Dougherty resigned effective upon the expiration of the 10-day notice period required by Rule 14f-1 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”).  In addition, effective upon the closing of the Financing, the Board appointed Arnold P. Kling as a director and then elected him as the Company’s president and elected Kirk M. Warshaw as the Company’s chief financial officer and secretary.
	In addition, on the Effective Date, the Company terminated (i) the Investor Rights Agreement dated September 18, 2003 among us, vSpring SBIC L.P. (“vSpring”) and certain of the investors set forth on Schedule A thereto and the Registration Rights Agreement dated May 25, 2005 among the Company, vSpring and certain of the investors set forth on Schedule I thereto in accordance with their respective terms and (ii) stock options exercisable for an aggregate of 246,714 shares of Common Stock (approximately 41% of the Company’s then outstanding stock options).
	On February 11, 2011, for the purpose of providing the Company with additional working capital, pursuant to an existing Credit Facility Agreement dated as of December 2, 2009 (the “Facility”) with Niobe, the Company issued to Niobe a senior secured convertible promissory note in the principal amount of $2 million (the “$2 Million Secured Convertible Note”). The $2 Million Secured Convertible Note was convertible into shares of Common Stock at a conversion price of $0.23 per share, for an aggregate of 8,695,652 shares of Common Stock (net of accrued interest thereon), bore interest at a rate of 3% per annum and had a maturity date of December 31, 2013. The original maturity was December 31, 2012 but in December 2012 Niobe agreed, for no consideration, to extend the maturity date to December 31, 2013.
	The $2 Million Secured Convertible Note was convertible at any time, by the holder, subject only to the requirement that the Company have sufficient authorized shares of Common Stock after taking into account all outstanding shares of Common Stock and the maximum number of shares issuable under all issued and outstanding convertible securities.  In addition, the $2 Million Secured Convertible Note would automatically be converted if the Company undertake certain Fundamental Transactions, as defined in the $2 Million Secured Convertible Note, (such as a merger, sale of all of the Company’s assets, exchange or tender offer, or reclassification of its stock or compulsory exchange).  The $2 Million Secured Convertible Note also provided for the adjustment of the conversion price in the event of stock dividends and stock splits, and provides for acceleration of maturity, at the holder’s option, upon an event of default, as defined in the $2 Million Secured Convertible Note. On August 27, 2013, Niobe elected to convert the principal and accrued interest of $2,155,000 under the $2 Million Secured Convertible Note into 9,369,565 shares of Common Stock.
	On February 1, 2012, the Company raised $1,000,000 of working capital pursuant to a loan from Niobe. The Company issued to Niobe a secured promissory note in the principal amount of $1,000,000 (the “February 2012 Secured Note”). The February 2012 Secured Note bore interest at a rate of 3% per annum and had a maturity date of February 1, 2014.
	On June 5, 2012, the Company raised an additional $1,000,000 of working capital pursuant to an incremental loan from Niobe and issued to Niobe a secured promissory note in the principal amount of $1,000,000, which bore interest at a rate of 3% per annum and had a maturity date of May 31, 2014 (the “June 2012 Secured Note”).
	On October 1, 2012, the Company raised $800,000 of additional working capital pursuant to an incremental loan from Niobe and issued to Niobe a secured promissory note in the principal amount of $800,000, which bore interest at a rate of 3% per annum and had a maturity date of October 1, 2014 (the “October 2012 Secured Note”).
	On December 3, 2012, the Company raised $700,000 of additional working capital pursuant to an incremental loan from Niobe and issued to Niobe a secured promissory note in the principal amount of $700,000, which bore interest at a rate of 3% per annum and had a maturity date of October 1, 2014 (the “December 2012 Secured Note”).
	Collectively, the February 2012 Secured Note, the June 2012 Secured Note, the October 2012 Secured Note and the December 2012 Secured Note are hereinafter referred to as the “2012 Secured Notes.”
	On January 18, 2013, the Company raised $2,500,000 of additional working capital pursuant to an incremental loan from Niobe and issued to Niobe a secured promissory note in the principal amount of $2,500,000, which bore interest at a rate of 3% per annum and had a maturity date of January 15, 2015 (the “January 2013 Secured Note”).
	On May 13, 2013, the Company raised $2,000,000 of additional working capital pursuant to an incremental loan from Niobe and issued to Niobe a secured promissory note in the principal amount of $2,000,000, which bore interest at a rate of 3% per annum and had a maturity date of May 13, 2015 (the “May 2013 Secured Note”).
	On August 27, 2013, the Company raised $1,000,000 of additional working capital pursuant to an incremental loan from Niobe and issued to Niobe a secured promissory note in the principal amount of $1,000,000, which bore interest at a rate of 3% per annum and had a maturity date of August 27, 2015. (the “August 2013 Secured Note”).
	Collectively, the January 2013 Secured Note, the May 2013 Secured Note, and the August 2013 Secured Note are hereinafter referred to as the “2013 Secured Notes.”
	Collectively, the 2012 Secured Notes and the 2013 Secured Notes represent a total of $9,000,000 in principal amount of loans from Niobe and are hereinafter referred to as the “Secured Notes.”
	On October 11, 2013, the Company issued a Consolidated, Amended and Restated Promissory Note to Niobe in the principal amount of $9,219,366 (the “Consolidated Note”).  The face amount of the Consolidated Note reflects the $9.0 million aggregate principal amount of the Secured Notes plus interest accrued at 3% per annum on each note from its respective date of issuance.  The terms of the Consolidated Note are identical to the Secured Notes except that: (a) the maturity date is September 1, 2015, which is after the latest maturity date of any of the Secured Notes; and (b) it provides for partial mandatory repayment in the event that the Company receives aggregate gross proceeds in excess of $7.5 million from a single or multiple “Liquidity Events” in an amount equal to twenty-five (25%) percent of such gross proceeds.  A “Liquidity Event” means (a) the sale of any of the Company’s equity, or equity-linked, securities, and (b) the receipt of proceeds, directly or indirectly related to a development and/or commercialization relationship entered into with an unaffiliated third party. In the Secured Notes, the entire principal amount of each note was due, at Niobe’s election, upon the consummation of an equity financing of $7.5 million or greater.  Consistent with the terms of the Secured Notes and related security agreements entered into, the Company’s obligations under the Consolidated Note are secured by a first priority perfected security interest in all of the Company’s assets pursuant to a Consolidated, Amended and Restated Security Agreement dated October 11, 2013 with Niobe.
	On January 23, 2014, the Company consummated a private placement financing to accredited investors of 471,334 shares of Common Stock at $6.00 per share, yielding gross proceeds of $2,828,000. No commissions were payable in connection with the financing transaction.  Proceeds of the financing will be used for working capital purposes, principally to fund ongoing clinical trials and studies and related activities.  The investors in the offering were granted piggy-back registration rights in connection with certain registration statements filed by the Company, subject to certain exceptions, including a registration statement filed in connection with a primary offering by the Company.

GOING_CONCERN

GOING CONCERN	12 Months Ended
	31-May-14
Going Concern Disclosure [Abstract]	'
GOING CONCERN	'
		3	GOING CONCERN
	Since inception, the Company has incurred an accumulated deficit of $73,587,282 through May 31, 2014. For the years ended May 31, 2014 and 2013, the Company had net losses of $11,852,229 and $6,280,234, respectively. The Company has used $4,623,891 and $4,733,349 of cash in operating activities for the years ended May 31 2014 and 2013, respectively. As of May 31, 2014, the Company had cash and cash equivalents of $1,614,758 and net working capital of $1,207,232. The Company has incurred negative cash flow from operating activities since its inception. The Company has spent, and subject to obtaining additional financing, expects to continue to spend, substantial amounts in connection with executing its business strategy, including continued development efforts relating to PRTX-100.
	The Company has no significant payments due on long-term obligations. However, the Company anticipates entering into significant contracts to perform product manufacturing and clinical trials in the future and that it will need to raise additional capital to fund the ongoing FDA approval process. If the Company is unable to obtain approval of its future IND applications or otherwise advance in the FDA approval process, its ability to sustain its operations would be significantly jeopardized.
	The most likely sources of additional financing include the private sale of the Company’s equity or debt securities. Additional capital that is required by the Company may not be available on reasonable terms, or at all.
	In February 2014, the Company filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (“SEC”) in connection with a prospective underwritten public offering of up to 3,000,000 shares of Common Stock. The Company does not presently have any commitment or understanding with any underwriter with respect to any offering. No assurance can be given that it will pursue or consummate an offering, or if it does, that it will be able to raise sufficient additional working capital to fund its operations and satisfy its debt obligations as they become due.

BASIS_OF_ACCOUNTING_AND_SUMMAR

BASIS OF ACCOUNTING AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	31-May-14
Accounting Policies [Abstract]	'
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	'
		4	BASIS OF ACCOUNTING AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires the Company to make estimates and assumptions affecting the reported amounts of assets, liabilities, and expense, and the disclosure of contingent assets and liabilities. Estimated amounts could differ from actual results.
	Loss per Common Share
	The Financial Accounting Standards Board (FASB) has issued accounting guidance “Earnings Per Share” that provides for the calculation of “Basic” and “Diluted” earnings per share. Basic earnings per share include no dilution and is computed by dividing the loss to common stockholders by the weighted average number of common shares outstanding for the period. All potentially dilutive securities have been excluded from the computations since they would be antidilutive. However, these dilutive securities could potentially dilute earnings per share in the future. As of May 31, 2014 and 2013, the Company had a total of 4,317,543 and 3,057,543, respectively, of potentially dilutive securities comprised solely of stock options.
	Share-Based Compensation
	The Company adopted the FASB accounting guidance for share based payment transactions. This standard requires the Company to measure the cost of employee services received in exchange for equity share options granted based on the grant-date fair value of the options. The cost is recognized as compensation expense over the vesting period of the options. The compensation cost included in operating expenses was $7,228,008 and $906,977 for the years ended May 31, 2014 and 2013, respectively and included both the compensation cost of stock options granted prior to but not yet vested as of June 1, 2006 and compensation cost for all options granted subsequent to May 31, 2006. No tax benefit was recorded as of May 31, 2014 in connection with these compensation costs due to the uncertainty regarding ultimate realization of certain net operating loss carry forwards.
	The Board adopted and the stockholders approved the 2003 Stock Option Plan on October 2003 and it was amended in October 2005. The plan was adopted to recognize the contributions made by the Company’s employees, officers, consultants, and directors, to provide those individuals with additional incentive to devote themselves to the Company’s future success, and to improve the Company’s ability to attract, retain and motivate individuals upon whom the Company’s growth and financial success depends. Under the plan, stock options may be granted as approved by the Board or the Compensation Committee. There are 900,000 shares reserved for grants of options under the plan, of which 37,000 have been issued and 800 were exercised. The Company has issued 2,980,543 stock options as stand-alone grants, of which 400 were exercised. Stock options vest pursuant to individual stock option agreements. No options granted under the plan are exercisable after the expiration of ten years (or less in the discretion of the Board or the Compensation Committee) from the date of the grant. The plan will continue in effect until terminated or amended by the Board.
	The accounting guidance requires the use of a valuation model to calculate the fair value of each stock-based award. The Company uses the Black-Scholes model to estimate the fair value of stock options granted based on the following assumptions:
	Expected Term or Life. The expected term or life of stock options granted represents the expected weighted average period of time from the date of grant to the estimated date that the stock option would be fully exercised. The weighted average expected option term was determined using a combination of the “simplified method” for plain vanilla options as allowed by the accounting guidance. The “simplified method” calculates the expected term as the average of the vesting term and original contractual term of the options.
	Expected Volatility. Expected volatility is a measure of the amount by which the Company’s stock price is expected to fluctuate. Expected volatility is based on the historical daily volatility of the price of Common Stock. The Company estimated the expected volatility of the stock options at grant date.
	Risk-Free Interest Rate. The risk-free interest rate is based on the implied yield on U.S. Treasury zero-coupon issues with remaining terms equivalent to the expected term of the Company’s stock-based awards.
	As of May 31, 2014, there were 4,317,543 stock options outstanding.  At May 31, 2014, the aggregate unrecognized compensation cost of unvested options, as determined using a Black-Scholes option valuation model was approximately $3,830,307 (net of estimated forfeitures and exclusive of 275,000 options yet to be earned or valued) and will be recognized over a weighted average period of eighteen months.  For the year ended May 31, 2014, the Company granted  1,300,000 stock options, with a fair value of $9,385,000 (net of estimated forfeitures and exclusive of 275,000 options yet to be earned or valued). 40,000 options expired and none were forfeited.
	The fair value of the options is estimated on the date of the grant using the Black-Scholes option pricing model with the following assumptions:
			Year Ended			Year Ended
			May 31, 2014			May 31, 2013
	Dividends per year			0			0
	Volatility percentage			418%-696%			418% - 426%
	Risk free interest rate			4	%		2.13	%
	Expected life (years)			10-May			10-Jul
	Weighted Average Fair Value		$	8.51		$	1.22
	Cash and Cash Equivalents
	For the purposes of reporting cash flows, the Company considers all cash accounts which are not subject to withdrawal restrictions or penalties, and highly liquid investments with original maturities of 60 days or less to be cash and cash equivalents. The cash and cash equivalent deposits are not insured by The Federal Deposit Insurance Corporation (“FDIC”).
	Intellectual Technology Property, Amortization
	The Company’s intellectual technology property was originally licensed from a former related party. This intellectual technology property was then assigned to the Company upon the dissolution of the related party. The cost of the intellectual technology property is being amortized over a 20-year period. Amortization expense is $1,020 and $1,020 for the years ended May 31, 2014 and 2013, respectively. The Company reviews the intellectual property for impairment on at least an annual basis in accordance with the accounting guidance for “Goodwill and Other Intangible Assets”; no impairment charge was recorded as of May 31, 2014. Amortization expense for the intellectual property will be $1,020 for each of the next five years.
	Income Taxes
	Income taxes are recognized using enacted tax rates, and are composed of taxes on financial accounting income that is adjusted for the requirement of current tax law and deferred taxes. Deferred taxes are accounted for using the liability method. Under this method, deferred tax assets and liabilities are recognized based on the difference between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. The Company does not expect to have current income taxes payable or deferred tax asset balances for the foreseeable future.
	The FASB accounting guidance for income taxes establishes the criterion that an individual tax position has to meet for some or all of the benefits of that position to be recognized in the Company’s financial statements. On initial application, ASC 740 must be applied to all tax positions for which the statute of limitations remains open. Only tax positions that meet the more-likely-than-not recognition threshold at the adoption date will be recognized or continue to be recognized. The cumulative effect of applying this accounting guidance is to be reported as an adjustment to retained earnings at the beginning of the period in which it is adopted.
	Research and Development
	Research and development costs are expensed as incurred and also include depreciation as reported above.
	Financial Instruments
	The Company adopted FASB ASC 820-Fair Value Measurements and Disclosure or ASC 820 for assets and liabilities measured at fair value on a recurring basis. ASC 820 establishes a common definition for fair value to be applied to existing generally accepted accounting principles that require the use of fair value measurements establishes a framework for measuring fair value and expands disclosure about such fair value measurements. The adoption of ASC 820 did not have an impact on the Company’s financial position or operating results, but did expand certain disclosures.
	ASC 820 defines fair value as the price that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Additionally, ASC 820 requires the use of valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. These inputs are prioritized below:
	Level 1: Observable inputs such as quoted market prices in active markets for identical assets or liabilities
	Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data
	Level 3: Unobservable inputs for which there is little or no market data, which require the use of the reporting entity’s own assumptions.
	The Company values its financial instruments as required by estimating their fair value. The estimated fair value amounts have been determined by the Company, using available market information or other appropriate valuation methodologies. However, considerable judgment is required in interpreting market data to develop estimates of fair value. Consequently, the estimates are not necessarily indicative of the amounts that could be realized or would be paid in a current market exchange.
	The Company’s financial instruments primarily consist of cash and cash equivalents, convertible debt, accounts payable and accruals.
	Cash and cash equivalents include money market securities and commercial paper that are considered to be highly liquid and easily tradable. These securities are valued using inputs observable in active markets for identical securities and are therefore classified as Level 1 within the fair value hierarchy.
	As of the balance sheet dates, the estimated fair values of the financial instruments were not materially different from their carrying values as presented due to the short maturities of these instruments and that the interest rates on the borrowings approximate those that would have been available for loans of similar remaining maturity and risk profile at respective year ends.
	New Accounting Pronouncements
	Except as set forth below, management does not believe that any other recently issued, but not yet effective, accounting standards could have a material effect on the accompanying consolidated financial statements. As new accounting pronouncements are issued, the Company will adopt those that are applicable under the circumstances.
	In June 2014, FASB issued Accounting Standards Update (“ASU”) No. 2014-10, “Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation”. The update removes all incremental financial reporting requirements from GAAP for development stage entities, including the removal of Topic 915 from the FASB Accounting Standards Codification. In addition, the update adds an example disclosure in Risks and Uncertainties (Topic 275) to illustrate one way that an entity that has not begun planned principal operations could provide information about the risks and uncertainties related to the company’s current activities. Furthermore, the update removes an exception provided to development stage entities in Consolidations (Topic 810) for determining whether an entity is a variable interest entity—which may change the consolidation analysis, consolidation decision, and disclosure requirements for a company that has an interest in a company in the development stage. The update is effective for the annual reporting periods beginning after December 15, 2014, including interim periods within that reporting period.  The Company has elected to adopt the provisions of this ASU early, accordingly all of the past disclosures and presentations on development stage accounting have been eliminated.
	In June 2014, FASB issued ASU No. 2014-12, “Compensation – Stock Compensation (Topic 718); Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period”. The amendments in this ASU apply to all reporting entities that grant their employees share-based payments in which the terms of the award provide that a performance target that affects vesting could be achieved after the requisite service period. The amendments require that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. A reporting entity should apply existing guidance in Topic 718 as it relates to awards with performance conditions that affect vesting to account for such awards. For all entities, the amendments in this ASU are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015. Earlier adoption is permitted. The effective date is the same for both public business entities and all other entities.
	Entities may apply the amendments in this ASU either (a) prospectively to all awards granted or modified after the effective date or (b) retrospectively to all awards with performance targets that are outstanding as of the beginning of the earliest annual period presented in the financial statements and to all new or modified awards thereafter. If retrospective transition is adopted, the cumulative effect of applying this Update as of the beginning of the earliest annual period presented in the financial statements should be recognized as an adjustment to the opening retained earnings balance at that date. Additionally, if retrospective transition is adopted, an entity may use hindsight in measuring and recognizing the compensation cost. The Company is currently reviewing the provisions of this ASU to determine if there will be any impact on its results of operations, cash flows or financial condition.

INCOME_TAXES

INCOME TAXES	12 Months Ended
	31-May-14
Income Tax Disclosure [Abstract]	'
INCOME TAXES	'
		5	INCOME TAXES
	For the years ended May 31, 2014 and 2013, the components of income tax benefit (expense) consist of the following:
			Year Ended			Year Ended
			May 31, 2014			May 31, 2013
	Current:
	Federal		$	0		$	0
	State			0			0
	Deferred:
	Federal			4,028,000			2,135,000
	State			711,000			377,000
	Tax credits			185,000			249,000
	Permanent timing difference			-2,999,000			-467,000
	Increase in valuation allowance			-1,925,000			-2,294,000
	Income tax benefit		$	0		$	0
	Income tax as a percentage of income for the year ended May 31, 2014 and 2013 differ from statutory federal income tax rates due to the following:
			Year Ended				Year Ended
			May 31, 2014				May 31, 2013
	Statutory federal income tax rate			-34	%			-34	%
	State income taxes, net of federal income tax impact			-6	%			-6	%
	Change in valuation allowance			17	%			37	%
	Permanent timing differences			25	%			7	%
	General business credit/other			-2	%			-4	%
				0	%			0	%
	The components of the net deferred tax asset as of May 31, 2014 and 2013 are as follows:
	Assets:		May 31, 2014			May 31, 2013
	Net operating losses		$	21,550,000		$	19,810,000
	Severance accrual			0			0
	General business credit			2,540,000			2,355,000
	Deferred tax assets			24,090,000			22,165,000
	Liability:
	Gross deferred tax asset			24,090,000			22,165,000
	Less valuation allowance			-24,090,000			-22,165,000
	Deferred tax asset, net of valuation allowance		$	0		$	0
	The gross deferred tax assets have been fully offset by a valuation allowance and has no uncertain tax positions to be disclosed.
	Internal Revenue Code Section 382 places a limitation on the amount of taxable income that can be offset by carryforwards after a change in control. As a result of these provisions, utilization of the NOL and tax credit carryforwards may be limited. Most of the deferred tax asset of net operating loss carryforwards and tax credits are subject to a Section 382 limitation on the amount to be utilized in a given year. The years May 31, 2010 through 2014 remain subject to examination by the relevant tax authorities.
	The Company is subject to U.S. federal income tax as well as income taxes of state jurisdiction. The Company is not currently under examination by any Federal or state jurisdiction. The federal statute of limitations and state are opened from inception forward. Management believes that the accrual for tax liabilities is adequate for all open years. This assessment relies on estimates and assumptions and may involve a series of complex judgments about future events. On the basis of present information, it is the opinion of the Company’s management that there are no pending assessments that will result in a material adverse effect on the Company’s financial statements over the next twelve months. The Company recognizes any interest accrued related to unrecognized tax benefits in interest expense and penalties in operating expenses for all periods presented. The Company has not recorded any material interest or penalties during any of the years presented.

RELATED_PARTIES

RELATED PARTIES	12 Months Ended
	31-May-14
Related Party Transactions [Abstract]	'
RELATED PARTIES	'
		6	RELATED PARTIES
	On November 11, 2009 (the “Effective Date”), the Company consummated a financing transaction (the “Financing”) in which it raised $3,000,000 of working capital pursuant to a Securities Purchase Agreement (the “Purchase Agreement”) with Niobe Ventures, LLC, a Delaware limited liability company (“Niobe”). Pursuant to the Purchase Agreement, the Company issued to Niobe (i) 8,695,652 restricted shares of Common Stock at a purchase price of $0.23 per share (or $2 million in the aggregate) and (ii) a senior secured convertible promissory note in the principal amount of $1 million convertible into shares of Common Stock at an initial conversion price equal to $0.23 per share (the “$1 Million Secured Note”). On February 11, 2011, Niobe converted the $1 Million Secured Note, including $37,500 of accrued interest thereon, into 4,510,870 shares of Common Stock.
	On February 11, 2011, for the purpose of providing the Company with additional working capital, pursuant to an existing Credit Facility Agreement dated as of December 2, 2009 (the “Facility”) with Niobe, the Company issued to Niobe a senior secured convertible promissory note in the principal amount of $2 million (the “$2 Million Secured Convertible Note”). The $2 Million Secured Convertible Note was convertible into shares of Common Stock at a conversion price of $0.23 per share, for an aggregate of 8,695,652 shares of Common Stock (net of accrued interest thereon), bore interest at a rate of 3% per annum and matured on December 31, 2013. The original maturity was December 31, 2012 but in December 2012 Niobe agreed, for no consideration, to extend the maturity date to December 31, 2013.
	The $2 Million Secured Convertible Note was convertible at any time, by the holder, subject only to the requirement that the Company have sufficient authorized shares of Common Stock after taking into account all outstanding shares of Common Stock and the maximum number of shares issuable under all issued and outstanding convertible securities.  In addition, the $2 Million Secured Convertible Note would automatically be converted if the Company undertake certain Fundamental Transactions, as defined in the $2 Million Secured Convertible Note, (such as a merger, sale of all of the Company’s assets, exchange or tender offer, or reclassification of its stock or compulsory exchange).  The $2 Million Secured Convertible Note also provided for the adjustment of the conversion price in the event of stock dividends and stock splits, and provides for acceleration of maturity, at the holder’s option, upon an event of default, as defined in the $2 Million Secured Convertible Note. On August 27, 2013, Niobe elected to convert the principal and accrued interest of $2,155,000 under the $2 Million Secured Convertible Note into 9,369,565 shares of Common Stock.
	On February 1, 2012, the Company raised $1,000,000 of working capital pursuant to a loan from Niobe. The Company issued to Niobe a secured promissory note in the principal amount of $1,000,000 (the “February 2012 Secured Note”). The February 2012 Secured Note bore interest at a rate of 3% per annum and had a maturity date of February 1, 2014.
	On June 5, 2012, the Company raised an additional $1,000,000 of working capital pursuant to an incremental loan from Niobe and issued to Niobe a secured promissory note in the principal amount of $1,000,000, which bore interest at a rate of 3% per annum and had a maturity date of May 31, 2014 (the “June 2012 Secured Note”).
	On October 1, 2012, the Company raised $800,000 of additional working capital pursuant to an incremental loan from Niobe and issued to Niobe a secured promissory note in the principal amount of $800,000, which bore interest at a rate of 3% per annum and had a maturity date of October 1, 2014 (the “October 2012 Secured Note”).
	On December 3, 2012, the Company raised $700,000 of additional working capital pursuant to an incremental loan from Niobe and issued to Niobe a secured promissory note in the principal amount of $700,000, which bore interest at a rate of 3% per annum and had a maturity date of October 1, 2014 (the “December 2012 Secured Note”).
	Collectively, the February 2012 Secured Note, the June 2012 Secured Note, the October 2012 Secured Note and the December 2012 Secured Note are hereinafter referred to as the “2012 Secured Notes.”
	On January 18, 2013, the Company raised $2,500,000 of additional working capital pursuant to an incremental loan from Niobe and issued to Niobe a secured promissory note in the principal amount of $2,500,000, which bore interest at a rate of 3% per annum and had a maturity date of January 15, 2015 (the “January 2013 Secured Note”).
	On May 13, 2013, the Company raised $2,000,000 of additional working capital pursuant to an incremental loan from Niobe and issued to Niobe a secured promissory note in the principal amount of $2,000,000, which bore interest at a rate of 3% per annum and had a maturity date of May 13, 2015 (the “May 2013 Secured Note”).
	On August 27, 2013, the Company raised $1,000,000 of additional working capital pursuant to an incremental loan from Niobe and issued to Niobe a secured promissory note in the principal amount of $1,000,000, which bore interest at a rate of 3% per annum and had a maturity date of August 27, 2015. (the “August 2013 Secured Note”).
	Collectively, the January 2013 Secured Note, the May 2013 Secured Note, and the August 2013 Secured Note are hereinafter referred to as the “2013 Secured Notes.”
	Collectively, the 2012 Secured Notes and the 2013 Secured Notes represent a total of $9,000,000 in principal amount of loans from Niobe and are hereinafter referred to as the “Secured Notes.”
	On October 11, 2013, the Company issued a Consolidated, Amended and Restated Promissory Note to Niobe in the principal amount of $9,219,366 (the “Consolidated Note”).  The face amount of the Consolidated Note reflects the $9.0 million aggregate principal amount of the Secured Notes plus interest accrued at 3% per annum on each note from its respective date of issuance.  The terms of the Consolidated Note are identical to the Secured Notes except that: (a) the maturity date is September 1, 2015, which is after the latest maturity date of any of the Secured Notes; and (b) it provides for partial mandatory repayment in the event that the Company receives aggregate gross proceeds in excess of $7.5 million from a single or multiple “Liquidity Events” in an amount equal to twenty-five (25%) percent of such gross proceeds.  A “Liquidity Event” means (a) the sale of any of the Company’s equity, or equity-linked, securities, and (b) the receipt of proceeds, directly or indirectly related to a development and/or commercialization relationship entered into with an unaffiliated third party. In the Secured Notes, the entire principal amount of each note was due, at Niobe’s election, upon the consummation of an equity financing of $7.5 million or greater.  Consistent with the terms of the Secured Notes and related security agreements entered into, the Company’s obligations under the Consolidated Note are secured by a first priority perfected security interest in all of the Company’s assets pursuant to a Consolidated, Amended and Restated Security Agreement dated October 11, 2013 with Niobe.
	All of the securities issued in the aforementioned financings were issued in reliance upon the exemption from the registration requirements of the Securities Act of 1933, as amended (the “Act”) pursuant to Section 4(a)(5) and Rule 506 of Regulation D thereof.  The offer, sale and issuance of such securities were made without general solicitation or advertising. The securities were offered and issued only to “accredited investors” as such term is defined in Rule 501 under the Act.
	Niobe, a majority stockholder of the Company and the holder of the Secured Notes, is controlled by the Company’s President and Director, Arnold P. Kling.
	During the fiscal year ended May 31, 2013, the Company issued an aggregate of 350,000 options to Mr. Warshaw. The 350,000 options issued during the fiscal year ended May 31, 2013 have a ten year life with an exercise price of $1.05. These options vested 50% upon issuance and the remainder will vest on May 22, 2014. The 350,000 options have been valued at $329,000 for which $164,500 of compensation expense has been recorded.
	During the fiscal year ended May 31, 2014, the Company issued an aggregate of 250,000 options to Mr. Elser. The 250,000 options issued during the fiscal year ended May 31, 2014 have a ten year life with an exercise price of $9.00. These options vested 33.33% upon issuance, another 33.33% will vest on the 12 month anniversary of their issuance, and the remainder will vest on May 4, 2016. The 250,000 options have been valued at $2,018,000 for which $896,887 of compensation expense has been recorded.

STOCK_OPTIONS

STOCK OPTIONS	12 Months Ended
	31-May-14
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
STOCK OPTIONS	'
		7	STOCK OPTIONS
	Prior to January 22, 2004, all options were issued as “stand alone” options. On January 22, 2004, the Board approved the Protalex, Inc. 2003 Stock Option Plan., and on October 25, 2005, the stockholders approved an amendment to the Protalex, Inc. 2003 Stock Option Plan to increase the authorized number of shares under the Plan from 300,000 to 900,000 which provides for incentive and non-qualified stock options to purchase a total of 900,000 shares of Common Stock. Under the terms of the plan, incentive options may not be granted at exercise prices less than the fair market value of the Common Stock at the date of the grant and non-qualified options shall not be granted at exercise prices equal to less than 85% of the fair market value of Common Stock at the date of the grant. Beginning January 1, 2005, all stock options are granted at fair market value. Vesting generally occurs ratably over forty eight months and is exercisable over a period no longer than ten years after the grant date. As of May 31, 2014, options to purchase 4,317,543 shares of Common Stock were outstanding, of which 37,000 were issued and 800 were exercised under the Company’s 2003 Stock Option Plan and the remaining 4,280,543 were issued and 400 were exercised as standalone options. As of May 31, 2014, options to purchase 3,350,876 shares of Common Stock are exercisable.
	The 1,000,000 options issued during the year ended May 31, 2013 are ten year options with exercise prices ranging from $1.05 to 1.39 per share. Some of these options vested 50% upon issuance and the remainder vest on their one year anniversary. Some options vest ratably over 2 years while some vest upon the achievement of certain benchmarks. The options issued during the year ended May 31, 2013 have been valued at $1,771,750 for which $735,667 of compensation expense has been recorded. The balance of the option expense recorded during the year ended May 31, 2013 is related to options issued in prior years.
	The 1,300,000 options issued during the year ended May 31, 2014 consisted of five year and ten year options with exercise prices ranging from $8.40 to $9.00 per share. Some of these options vested 50% upon issuance and the remainder vest on their one year anniversary. Some options vest ratably over 2 years while some vest upon the achievement of certain benchmarks. The options issued during the year ended May 31, 2014 have been valued at $9,385,000 for which $5,789,996 of compensation expense has been recorded. The balance of the option expense recorded during the year ended May 31, 2014 is related to options issued in prior years.
	A summary of the Common Stock option activity for employees, directors, officers and consultants as of May 31, 2014 and for the three years then ended is as follows:
			Shares	Weighted		Weighted
				Average Exercise		Average Remaining
				Price		Contractual Term
						(Years)
	Outstanding at May 31, 2011		1,538,927	$	1.99			3.7
	Granted		750,000	$	1.01			10
	Exercised		0		0			0
	Forfeited		0		0			0
	Expired		-20,000		0			0
	Outstanding at May 31, 2012		2,268,927	$	1.27			7.65
	Granted		1,000,000	$	1.22			10
	Exercised		0		0			0
	Forfeited		0		0			0
	Expired		-211,385	$	7.52			0
	Outstanding at May 31, 2013		3,057,542	$	1.09			8.08
	Granted		1,300,000		8.51			5.83
	Exercised		0		0			0
	Forfeited		0		0			0
	Expired		-40,000		7.5			0
	Outstanding May 31, 2014		4,317,543	$	3.26			6,67
	Exercisable at May 31, 2014		3,350,876	$	3.43			7.83
	The outstanding and exercisable stock options as of May 31, 2014 and 2013 had an intrinsic value of $20,782,678 and $351,821, respectively.
	The 1,300,000 options issued during the year were issued at an exercise price that was equal to the market price at the time the options were granted.
	The following summarizes certain information regarding stock options at May 31, 2014:
	Exercise Price		Number		Weighted		Weighted		Number		Weighted	Weighted
	Range				Average		Average				Average	Average
					Exercise Price		Remaining Life				Exercise Price	Remaining Life
							(Years)					(years)
	$0.00 – 1.00		1,230,543	$	0.44		6.07		1,230,543	$	0.44	6.07
	$1.01 – 5.00		1,750,000	$	1.13		7.95		1,575,000		1.32	7.95
	$5.01 – 10.00		1,300,000	$	8.51		5.83		508,333	$	8.51	5.25
	$10.01 – 15.00		37,000	$	13.86		1.6		37,000	$	13.86	1.6
			4,317,543	$	3.26		6.67		3,350,876	$	2.23	6.6

SENIOR_SECURED_NOTE_RELATED_PA

SENIOR SECURED NOTE - RELATED PARTY	12 Months Ended
	31-May-14
Debt Disclosure [Abstract]	'
SENIOR SECURED NOTE - RELATED PARTY	'
	8. SENIOR SECURED NOTE – RELATED PARTY
	On February 1, 2012, the Company raised $1,000,000 of working capital pursuant to a loan from Niobe. The Company issued to Niobe a secured promissory note in the principal amount of $1,000,000 (the “February 2012 Secured Note”). The February 2012 Secured Note bore interest at a rate of 3% per annum and had a maturity date of February 1, 2014.
	On June 5, 2012, the Company raised an additional $1,000,000 of working capital pursuant to an incremental loan from Niobe and issued to Niobe a secured promissory note in the principal amount of $1,000,000, which bore interest at a rate of 3% per annum and had a maturity date of May 31, 2014 (the “June 2012 Secured Note”).
	On October 1, 2012, the Company raised $800,000 of additional working capital pursuant to an incremental loan from Niobe and issued to Niobe a secured promissory note in the principal amount of $800,000, which bore interest at a rate of 3% per annum and had a maturity date of October 1, 2014 (the “October 2012 Secured Note”).
	On December 3, 2012, the Company raised $700,000 of additional working capital pursuant to an incremental loan from Niobe and issued to Niobe a secured promissory note in the principal amount of $700,000, which bore interest at a rate of 3% per annum and had a maturity date of October 1, 2014 (the “December 2012 Secured Note”).
	Collectively, the February 2012 Secured Note, the June 2012 Secured Note, the October 2012 Secured Note and the December 2012 Secured Note are hereinafter referred to as the “2012 Secured Notes.”
	On January 18, 2013, the Company raised $2,500,000 of additional working capital pursuant to an incremental loan from Niobe and issued to Niobe a secured promissory note in the principal amount of $2,500,000, which bore interest at a rate of 3% per annum and had a maturity date of January 15, 2015 (the “January 2013 Secured Note”).
	On May 13, 2013, the Company raised $2,000,000 of additional working capital pursuant to an incremental loan from Niobe and issued to Niobe a secured promissory note in the principal amount of $2,000,000, which bore interest at a rate of 3% per annum and had a maturity date of May 13, 2015 (the “May 2013 Secured Note”).
	On August 27, 2013, the Company raised $1,000,000 of additional working capital pursuant to an incremental loan from Niobe and issued to Niobe a secured promissory note in the principal amount of $1,000,000, which bore interest at a rate of 3% per annum and had a maturity date of August 27, 2015. (the “August 2013 Secured Note”).
	Collectively, the January 2013 Secured Note, the May 2013 Secured Note, and the August 2013 Secured Note are hereinafter referred to as the “2013 Secured Notes.”
	Collectively, the 2012 Secured Notes and the 2013 Secured Notes represent a total of $9,000,000 in principal amount of loans from Niobe and are hereinafter referred to as the “Secured Notes.”
	On October 11, 2013, the Company issued a Consolidated, Amended and Restated Promissory Note to Niobe in the principal amount of $9,219,366 (the “Consolidated Note”).  The face amount of the Consolidated Note reflects the $9.0 million aggregate principal amount of the Secured Notes plus interest accrued at 3% per annum on each note from its respective date of issuance.  The terms of the Consolidated Note are identical to the Secured Notes except that: (a) the maturity date is September 1, 2015, which is after the latest maturity date of any of the Secured Notes; and (b) it provides for partial mandatory repayment in the event that the Company receives aggregate gross proceeds in excess of $7.5 million from a single or multiple “Liquidity Events” in an amount equal to twenty-five (25%) percent of such gross proceeds.  A “Liquidity Event” means (a) the sale of any of the Company’s equity, or equity-linked, securities, and (b) the receipt of proceeds, directly or indirectly related to a development and/or commercialization relationship entered into with an unaffiliated third party. In the Secured Notes, the entire principal amount of each note was due, at Niobe’s election, upon the consummation of an equity financing of $7.5 million or greater.  Consistent with the terms of the Secured Notes and related security agreements entered into, the Company’s obligations under the Consolidated Note are secured by a first priority perfected security interest in all of the Company’s assets pursuant to a Consolidated, Amended and Restated Security Agreement dated October 11, 2013 with Niobe.

STOCKHOLDERS_EQUITY

STOCKHOLDERS EQUITY	12 Months Ended
	31-May-14
Stockholders Equity Note [Abstract]	'
STOCKHOLDERS EQUITY	'
		9	STOCKHOLDERS EQUITY
	On December 8, 2010, the Company effected a reverse stock split of the outstanding shares of its common stock, with par value of $0.00001 per share (“Common Stock”), on the basis of one (1) share of Common Stock for each five (5) shares of Common Stock outstanding. All references in these financial statements and notes to financial statements to number of shares, price per share and weighted average number of shares outstanding of Common Stock prior to this reverse stock split have been adjusted to reflect the reverse stock split on a retroactive basis unless otherwise noted,
	On December 8, 2010, the Company authorized one (1) million shares of a “blank check” class of preferred stock.
	On January 23, 2014, the Company consummated a private placement financing to accredited investors of 471,334 shares of Common Stock at $6.00 per share, yielding gross proceeds of $2,828,000. No commissions were payable in connection with the financing transaction.  Proceeds of the financing will be used for working capital purposes, principally to fund ongoing clinical trials and studies and related activities.  The investors in the offering were granted piggy-back registration rights in connection with certain registration statements filed by the Company, subject to certain exceptions, including a registration statement filed in connection with a primary offering by the Company.

SUBSEQUENT_EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	31-May-14
Subsequent Events [Abstract]	'
SUBSEQUENT EVENTS	'
	10. SUBSEQUENT EVENTS
	In June 2014 the Company issued non-qualified stock options for an aggregate of 200,000 shares of Common Stock with an exercise price of $8.22 per share to two consultants. The option expires five years from the date of grant.
	The Company has evaluated subsequent events and has determined that there were no other subsequent events to recognize or disclose in these financial statements.

BASIS_OF_ACCOUNTING_AND_SUMMAR1

BASIS OF ACCOUNTING AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	31-May-14
Accounting Policies [Abstract]	'
Estimates	'
	Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires the Company to make estimates and assumptions affecting the reported amounts of assets, liabilities, and expense, and the disclosure of contingent assets and liabilities. Estimated amounts could differ from actual results.
Loss per Common Share	'
	Loss per Common Share
	The Financial Accounting Standards Board (FASB) has issued accounting guidance “Earnings Per Share” that provides for the calculation of “Basic” and “Diluted” earnings per share. Basic earnings per share include no dilution and is computed by dividing the loss to common stockholders by the weighted average number of common shares outstanding for the period. All potentially dilutive securities have been excluded from the computations since they would be antidilutive. However, these dilutive securities could potentially dilute earnings per share in the future. As of May 31, 2014 and 2013, the Company had a total of 4,317,543 and 3,057,543, respectively, of potentially dilutive securities comprised solely of stock options.
Share Based Compensation	'
	Share-Based Compensation
	The Company adopted the FASB accounting guidance for share based payment transactions. This standard requires the Company to measure the cost of employee services received in exchange for equity share options granted based on the grant-date fair value of the options. The cost is recognized as compensation expense over the vesting period of the options. The compensation cost included in operating expenses was $7,228,008 and $906,977 for the years ended May 31, 2014 and 2013, respectively and included both the compensation cost of stock options granted prior to but not yet vested as of June 1, 2006 and compensation cost for all options granted subsequent to May 31, 2006. No tax benefit was recorded as of May 31, 2014 in connection with these compensation costs due to the uncertainty regarding ultimate realization of certain net operating loss carry forwards.
	The Board adopted and the stockholders approved the 2003 Stock Option Plan on October 2003 and it was amended in October 2005. The plan was adopted to recognize the contributions made by the Company’s employees, officers, consultants, and directors, to provide those individuals with additional incentive to devote themselves to the Company’s future success, and to improve the Company’s ability to attract, retain and motivate individuals upon whom the Company’s growth and financial success depends. Under the plan, stock options may be granted as approved by the Board or the Compensation Committee. There are 900,000 shares reserved for grants of options under the plan, of which 37,000 have been issued and 800 were exercised. The Company has issued 2,980,543 stock options as stand-alone grants, of which 400 were exercised. Stock options vest pursuant to individual stock option agreements. No options granted under the plan are exercisable after the expiration of ten years (or less in the discretion of the Board or the Compensation Committee) from the date of the grant. The plan will continue in effect until terminated or amended by the Board.
	The accounting guidance requires the use of a valuation model to calculate the fair value of each stock-based award. The Company uses the Black-Scholes model to estimate the fair value of stock options granted based on the following assumptions:
	Expected Term or Life. The expected term or life of stock options granted represents the expected weighted average period of time from the date of grant to the estimated date that the stock option would be fully exercised. The weighted average expected option term was determined using a combination of the “simplified method” for plain vanilla options as allowed by the accounting guidance. The “simplified method” calculates the expected term as the average of the vesting term and original contractual term of the options.
	Expected Volatility. Expected volatility is a measure of the amount by which the Company’s stock price is expected to fluctuate. Expected volatility is based on the historical daily volatility of the price of Common Stock. The Company estimated the expected volatility of the stock options at grant date.
	Risk-Free Interest Rate. The risk-free interest rate is based on the implied yield on U.S. Treasury zero-coupon issues with remaining terms equivalent to the expected term of the Company’s stock-based awards.
	As of May 31, 2014, there were 4,317,543 stock options outstanding.  At May 31, 2014, the aggregate unrecognized compensation cost of unvested options, as determined using a Black-Scholes option valuation model was approximately $3,830,307 (net of estimated forfeitures and exclusive of 275,000 options yet to be earned or valued) and will be recognized over a weighted average period of eighteen months.  For the year ended May 31, 2014, the Company granted  1,300,000 stock options, with a fair value of $9,385,000 (net of estimated forfeitures and exclusive of 275,000 options yet to be earned or valued). 40,000 options expired and none were forfeited.
	The fair value of the options is estimated on the date of the grant using the Black-Scholes option pricing model with the following assumptions:
		Year Ended			Year Ended
		May 31, 2014			May 31, 2013
	Dividends per year		0			0
	Volatility percentage		418%-696%			418% - 426%
	Risk free interest rate		4	%		2.13	%
	Expected life (years)		10-May			10-Jul
	Weighted Average Fair Value	$	8.51		$	1.22
Cash and Cash Equivalents	'
	Cash and Cash Equivalents
	For the purposes of reporting cash flows, the Company considers all cash accounts which are not subject to withdrawal restrictions or penalties, and highly liquid investments with original maturities of 60 days or less to be cash and cash equivalents. The cash and cash equivalent deposits are not insured by The Federal Deposit Insurance Corporation (“FDIC”).
Intellectual Technology Property, Amortization	'
	Intellectual Technology Property, Amortization
	The Company’s intellectual technology property was originally licensed from a former related party. This intellectual technology property was then assigned to the Company upon the dissolution of the related party. The cost of the intellectual technology property is being amortized over a 20-year period. Amortization expense is $1,020 and $1,020 for the years ended May 31, 2014 and 2013, respectively. The Company reviews the intellectual property for impairment on at least an annual basis in accordance with the accounting guidance for “Goodwill and Other Intangible Assets”; no impairment charge was recorded as of May 31, 2014. Amortization expense for the intellectual property will be $1,020 for each of the next five years.
Income Taxes	'
	Income Taxes
	Income taxes are recognized using enacted tax rates, and are composed of taxes on financial accounting income that is adjusted for the requirement of current tax law and deferred taxes. Deferred taxes are accounted for using the liability method. Under this method, deferred tax assets and liabilities are recognized based on the difference between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. The Company does not expect to have current income taxes payable or deferred tax asset balances for the foreseeable future.
	The FASB accounting guidance for income taxes establishes the criterion that an individual tax position has to meet for some or all of the benefits of that position to be recognized in the Company’s financial statements. On initial application, ASC 740 must be applied to all tax positions for which the statute of limitations remains open. Only tax positions that meet the more-likely-than-not recognition threshold at the adoption date will be recognized or continue to be recognized. The cumulative effect of applying this accounting guidance is to be reported as an adjustment to retained earnings at the beginning of the period in which it is adopted.
Research and Development	'
	Research and Development
	Research and development costs are expensed as incurred and also include depreciation as reported above.
Financial Instruments	'
	Financial Instruments
	The Company adopted FASB ASC 820-Fair Value Measurements and Disclosure or ASC 820 for assets and liabilities measured at fair value on a recurring basis. ASC 820 establishes a common definition for fair value to be applied to existing generally accepted accounting principles that require the use of fair value measurements establishes a framework for measuring fair value and expands disclosure about such fair value measurements. The adoption of ASC 820 did not have an impact on the Company’s financial position or operating results, but did expand certain disclosures.
	ASC 820 defines fair value as the price that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Additionally, ASC 820 requires the use of valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. These inputs are prioritized below:
	Level 1: Observable inputs such as quoted market prices in active markets for identical assets or liabilities
	Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data
	Level 3: Unobservable inputs for which there is little or no market data, which require the use of the reporting entity’s own assumptions.
	The Company values its financial instruments as required by estimating their fair value. The estimated fair value amounts have been determined by the Company, using available market information or other appropriate valuation methodologies. However, considerable judgment is required in interpreting market data to develop estimates of fair value. Consequently, the estimates are not necessarily indicative of the amounts that could be realized or would be paid in a current market exchange.
	The Company’s financial instruments primarily consist of cash and cash equivalents, convertible debt, accounts payable and accruals.
	Cash and cash equivalents include money market securities and commercial paper that are considered to be highly liquid and easily tradable. These securities are valued using inputs observable in active markets for identical securities and are therefore classified as Level 1 within the fair value hierarchy.
	As of the balance sheet dates, the estimated fair values of the financial instruments were not materially different from their carrying values as presented due to the short maturities of these instruments and that the interest rates on the borrowings approximate those that would have been available for loans of similar remaining maturity and risk profile at respective year ends.
New Accounting Pronouncements	'
	New Accounting Pronouncements
	Except as set forth below, management does not believe that any other recently issued, but not yet effective, accounting standards could have a material effect on the accompanying consolidated financial statements. As new accounting pronouncements are issued, the Company will adopt those that are applicable under the circumstances.
	In June 2014, FASB issued Accounting Standards Update (“ASU”) No. 2014-10, “Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation”. The update removes all incremental financial reporting requirements from GAAP for development stage entities, including the removal of Topic 915 from the FASB Accounting Standards Codification. In addition, the update adds an example disclosure in Risks and Uncertainties (Topic 275) to illustrate one way that an entity that has not begun planned principal operations could provide information about the risks and uncertainties related to the company’s current activities. Furthermore, the update removes an exception provided to development stage entities in Consolidations (Topic 810) for determining whether an entity is a variable interest entity—which may change the consolidation analysis, consolidation decision, and disclosure requirements for a company that has an interest in a company in the development stage. The update is effective for the annual reporting periods beginning after December 15, 2014, including interim periods within that reporting period.  The Company has elected to adopt the provisions of this ASU early, accordingly all of the past disclosures and presentations on development stage accounting have been eliminated.
	In June 2014, FASB issued ASU No. 2014-12, “Compensation – Stock Compensation (Topic 718); Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period”. The amendments in this ASU apply to all reporting entities that grant their employees share-based payments in which the terms of the award provide that a performance target that affects vesting could be achieved after the requisite service period. The amendments require that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. A reporting entity should apply existing guidance in Topic 718 as it relates to awards with performance conditions that affect vesting to account for such awards. For all entities, the amendments in this ASU are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015. Earlier adoption is permitted. The effective date is the same for both public business entities and all other entities.
	Entities may apply the amendments in this ASU either (a) prospectively to all awards granted or modified after the effective date or (b) retrospectively to all awards with performance targets that are outstanding as of the beginning of the earliest annual period presented in the financial statements and to all new or modified awards thereafter. If retrospective transition is adopted, the cumulative effect of applying this Update as of the beginning of the earliest annual period presented in the financial statements should be recognized as an adjustment to the opening retained earnings balance at that date. Additionally, if retrospective transition is adopted, an entity may use hindsight in measuring and recognizing the compensation cost. The Company is currently reviewing the provisions of this ASU to determine if there will be any impact on its results of operations, cash flows or financial condition.

BASIS_OF_ACCOUNTING_AND_SUMMAR2

BASIS OF ACCOUNTING AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	31-May-14
Accounting Policies [Abstract]	'
Fair Value of Assumptions of Options Estimated On Grant Date	'
	The fair value of the options is estimated on the date of the grant using the Black-Scholes option pricing model with the following assumptions:
		Year Ended			Year Ended
		May 31, 2014			May 31, 2013
	Dividends per year		0			0
	Volatility percentage		418%-696%			418% - 426%
	Risk free interest rate		4	%		2.13	%
	Expected life (years)		10-May			10-Jul
	Weighted Average Fair Value	$	8.51		$	1.22

INCOME_TAXES_Tables

INCOME TAXES (Tables)	12 Months Ended
	31-May-14
Income Tax Disclosure [Abstract]	'
Schedule of Components of Income Tax Expense (Benefit)	'
	For the years ended May 31, 2014 and 2013, the components of income tax benefit (expense) consist of the following:
		Year Ended			Year Ended
		May 31, 2014			May 31, 2013
	Current:
	Federal	$	0		$	0
	State		0			0
	Deferred:
	Federal		4,028,000			2,135,000
	State		711,000			377,000
	Tax credits		185,000			249,000
	Permanent timing difference		-2,999,000			-467,000
	Increase in valuation allowance		-1,925,000			-2,294,000
	Income tax benefit	$	0		$	0
Schedule of Effective Income Tax Rate Reconciliation	'
	Income tax as a percentage of income for the year ended May 31, 2014 and 2013 differ from statutory federal income tax rates due to the following:
		Year Ended				Year Ended
		May 31, 2014				May 31, 2013
	Statutory federal income tax rate		-34	%			-34	%
	State income taxes, net of federal income tax impact		-6	%			-6	%
	Change in valuation allowance		17	%			37	%
	Permanent timing differences		25	%			7	%
	General business credit/other		-2	%			-4	%
			0	%			0	%
Schedule of Deferred Tax Assets and Liabilities	'
	The components of the net deferred tax asset as of May 31, 2014 and 2013 are as follows:
	Assets:	May 31, 2014			May 31, 2013
	Net operating losses	$	21,550,000		$	19,810,000
	Severance accrual		0			0
	General business credit		2,540,000			2,355,000
	Deferred tax assets		24,090,000			22,165,000
	Liability:
	Gross deferred tax asset		24,090,000			22,165,000
	Less valuation allowance		-24,090,000			-22,165,000
	Deferred tax asset, net of valuation allowance	$	0		$	0

STOCK_OPTIONS_Tables

STOCK OPTIONS (Tables)	12 Months Ended
	31-May-14
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Schedule of Share-based Compensation, Stock Options, Activity	'
	A summary of the Common Stock option activity for employees, directors, officers and consultants as of May 31, 2014 and for the three years then ended is as follows:
		Shares	Weighted		Weighted
			Average Exercise		Average Remaining
			Price		Contractual Term
					(Years)
	Outstanding at May 31, 2011	1,538,927	$	1.99			3.7
	Granted	750,000	$	1.01			10
	Exercised	0		0			0
	Forfeited	0		0			0
	Expired	-20,000		0			0
	Outstanding at May 31, 2012	2,268,927	$	1.27			7.65
	Granted	1,000,000	$	1.22			10
	Exercised	0		0			0
	Forfeited	0		0			0
	Expired	-211,385	$	7.52			0
	Outstanding at May 31, 2013	3,057,542	$	1.09			8.08
	Granted	1,300,000		8.51			5.83
	Exercised	0		0			0
	Forfeited	0		0			0
	Expired	-40,000		7.5			0
	Outstanding May 31, 2014	4,317,543	$	3.26			6,67
	Exercisable at May 31, 2014	3,350,876	$	3.43			7.83
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range	'
	The following summarizes certain information regarding stock options at May 31, 2014:
	Exercise Price	Number		Weighted		Weighted		Number		Weighted	Weighted
	Range			Average		Average				Average	Average
				Exercise Price		Remaining Life				Exercise Price	Remaining Life
						(Years)					(years)
	$0.00 – 1.00	1,230,543	$	0.44		6.07		1,230,543	$	0.44	6.07
	$1.01 – 5.00	1,750,000	$	1.13		7.95		1,575,000		1.32	7.95
	$5.01 – 10.00	1,300,000	$	8.51		5.83		508,333	$	8.51	5.25
	$10.01 – 15.00	37,000	$	13.86		1.6		37,000	$	13.86	1.6
		4,317,543	$	3.26		6.67		3,350,876	$	2.23	6.6

ORGANIZATION_AND_BUSINESS_ACTI1

ORGANIZATION AND BUSINESS ACTIVITIES - Additional Information (Detail) (USD $)	31-May-14	31-May-13	Dec. 08, 2010
Organization and Nature Of Operations [Line Items]	'	'	'
Reverse stock split, Common stock, par value	$0.00	$0.00	$0.00

CHANGE_OF_OWNERSHIP_TRANSACTIO1

CHANGE OF OWNERSHIP TRANSACTION - Additional Information (Detail) (USD $)

1 Months Ended

1 Months Ended

0 Months Ended

0 Months Ended

Feb. 28, 2014

25-May-05

25-May-05

Jan. 23, 2014

Oct. 11, 2013

Feb. 01, 2012

Aug. 27, 2013

13-May-13

Jan. 18, 2013

Dec. 03, 2012

Oct. 01, 2012

Jun. 05, 2012

Feb. 01, 2012

31-May-14

Nov. 11, 2009

Feb. 11, 2011

Nov. 11, 2009

Feb. 11, 2011

Investor Rights Agreement

Private Placement

Senior Secured Note

Niobe Ventures LLC

Niobe Ventures LLC

Niobe Ventures LLC

Niobe Ventures LLC

Niobe Ventures LLC

Niobe Ventures LLC

Niobe Ventures LLC

Niobe Ventures LLC

Niobe Ventures LLC

Niobe Ventures LLC

Niobe Ventures LLC

Niobe Ventures LLC

Credit Facility Agreement

Senior Secured Note

Senior Secured Note

Senior Secured Note

Senior Secured Note

Senior Secured Note

Senior Secured Note

Senior Secured Note

Senior Secured Note

Securities Purchase Agreement

Securities Purchase Agreement

Securities Purchase Agreement

Niobe Ventures LLC

Senior Secured Note

Senior Secured Note

Senior Secured Note

Class of Stock [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Additional working capital raised

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$3,000,000

'

'

'

Restricted shares of common stock issued

3,000,000

'

'

471,334

'

'

'

'

'

'

'

'

'

'

8,695,652

'

'

8,695,652

Common Stock issued, per share

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.23

'

'

'

Restricted shares of common stock issued, value

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,000,000

'

'

'

Senior secured convertible promissory note

'

'

'

'

'

'

2,000,000

'

'

'

'

'

'

'

'

1,000,000

1,000,000

2,000,000

Accrued interest on senior secured convertible promissory note

'

'

'

'

'

'

2,155,000

'

'

'

'

'

'

'

'

37,500

'

'

Senior secured convertible promissory note, conversion price per share

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.23

$0.23

Shares of common stock issuable upon conversion of senior secured convertible promissory note

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,510,870

'

'

Senior secured convertible promissory note, maturity date

'

'

'

'

1-Sep-15

1-Feb-14

27-Aug-15

13-May-15

15-Jan-15

1-Oct-14

1-Oct-14

31-May-14

1-Feb-14

'

'

'

'

31-Dec-12

Senior secured convertible promissory note, extended maturity date

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

31-Dec-13

Debt instrument, interest rate, effective percentage

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3.00%

Proceeds from secured notes payable

'

'

'

'

'

'

1,000,000

2,000,000

2,500,000

700,000

800,000

1,000,000

1,000,000

'

'

'

'

'

Debt instrument, face amount

'

'

'

'

9,000,000

'

1,000,000

2,000,000

2,500,000

700,000

800,000

1,000,000

1,000,000

9,000,000

'

'

'

'

Secured note payable, interest rate

'

'

'

'

3.00%

'

3.00%

3.00%

3.00%

3.00%

3.00%

3.00%

3.00%

'

'

'

'

'

Debt Conversion, Converted Instrument, Shares Issued

'

'

'

'

'

'

9,369,565

'

'

'

'

'

'

'

'

'

'

'

Debt instrument carrying amount

'

'

'

'

9,219,366

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from Repayments of secured debt

'

'

'

'

7,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Terms of consolidated note identical to secured notes

'

'

'

'

'(a) the maturity date is September 1, 2015, which is after the latest maturity date of any of the Secured Notes; and (b) it provides for partial mandatory repayment in the event that the Company receives aggregate gross proceeds in excess of $7.5 million from a single or multiple “Liquidity Events” in an amount equal to twenty-five (25%) percent of such gross proceeds.

'

'

'

'

'

'

'

'

'

'

'

'

'

Consummation of equity financing, amount

'

'

'

'

7,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number

'

'

246,714

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage For Stock Options Outstanding

'

41.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share Price

'

'

'

$6

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from Issuance of Private Placement

'

'

'

$2,828,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

GOING_CONCERN_Additional_Infor

GOING CONCERN - Additional Information (Detail) (USD $)	1 Months Ended	12 Months Ended
	Feb. 28, 2014	31-May-14	31-May-13	31-May-12
Cash Flow Supplemental Disclosures [Line Items]	'	'	'	'
Deficit accumulated during the development stage	'	$73,587,282	'	'
Net loss	'	11,852,229	6,280,234	'
Cash used in operating activities	'	4,623,891	4,733,349	'
Cash and cash equivalents	'	1,614,758	2,457,046	190,395
Net working capital deficit	'	$1,207,232	'	'
Stock Issued During Period Shares New Issues	3,000,000	'	'	'

BASIS_OF_ACCOUNTING_AND_SUMMAR3

BASIS OF ACCOUNTING AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Detail) (USD $)	12 Months Ended
	31-May-14	31-May-13
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Compensation cost included in operating expenses	$5,789,996	$735,667
Share based compensation, number of options issued during period	4,280,543	'
Aggregate unrecognized compensation cost of unvested options	3,830,307	'
Stock option fair value	9,385,000	1,771,750
Amortization period for intellectual property	'20 years	'
Amortization expenses	1,020	1,020
Future amortization expenses	1,020	'
Unrecognized compensation cost of unvested options not yet earned or valued	275,000	'
Non Plan Option Grants	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term	'10 years	'
Stock Incentive Plan 2003	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Number of shares reserved for grants of options	900,000	'
Share based compensation, number of options issued during period	37,000	'
Share based compensation, number of options exercised during period	800	'
Stand-Alone Grants	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Share based compensation, number of options issued during period	2,980,543	'
Share based compensation, number of options exercised during period	400	'
Operating Expense	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Compensation cost included in operating expenses	$7,228,008	$906,977
Stock Option	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Potentially dilutive securities	4,317,543	3,057,543
Share based compensation, number of stock options outstanding	4,317,543	'
Share based compensation, number of stock options granted during period	1,300,000	'
Share based compensation, number of stock options expired during period	40,000	'

Fair_Value_of_Assumptions_of_O

Fair Value of Assumptions of Options Estimated on Grant Date (Detail) (USD $)	12 Months Ended
	31-May-14	31-May-13
Assumptions used to Determine Fair Value Options [Line Items]	'	'
Dividends per year	$0	$0
Risk free interest rate	4.00%	2.13%
Weighted Average Fair Value	$8.51	$1.22
Minimum	'	'
Assumptions used to Determine Fair Value Options [Line Items]	'	'
Volatility percentage	418.00%	418.00%
Expected life (years)	'5 years	'7 years
Maximum	'	'
Assumptions used to Determine Fair Value Options [Line Items]	'	'
Volatility percentage	696.00%	426.00%
Expected life (years)	'10 years	'10 years

Components_of_Income_Tax_Benef

Components of Income Tax Benefit (Expense) (Detail) (USD $)	12 Months Ended
	31-May-14	31-May-13
Current:	'	'
Federal	$0	$0
State	0	0
Deferred:	'	'
Federal	4,028,000	2,135,000
State	711,000	377,000
Tax credits	185,000	249,000
Permanent timing difference	-2,999,000	-467,000
Increase in valuation allowance	-1,925,000	-2,294,000
Income tax benefit	$0	$0

Income_Tax_as_a_Percentage_of_

Income Tax as a Percentage of Income (Detail)	12 Months Ended
	31-May-14	31-May-13
Effective Income Tax Rate Reconciliation, Percent [Line Items]	'	'
Statutory federal income tax rate	-34.00%	-34.00%
State income taxes, net of federal income tax impact	-6.00%	-6.00%
Change in valuation allowance	17.00%	37.00%
Permanent timing differences	25.00%	7.00%
General business credit/other	-2.00%	-4.00%
Effective Income Tax Rate Reconciliation, Percent, Total	0.00%	0.00%

Components_of_Deferred_Tax_Ass

Components of Deferred Tax Assets and Liabilities (Detail) (USD $)	31-May-14	31-May-13
Assets:	'	'
Net operating losses	$21,550,000	$19,810,000
Severance accrual	0	0
General business credit	2,540,000	2,355,000
Deferred tax assets	24,090,000	22,165,000
Liability:	'	'
Gross deferred tax asset	24,090,000	22,165,000
Less valuation allowance	-24,090,000	-22,165,000
Deferred tax asset, net of valuation allowance	$0	$0

RELATED_PARTIES_Additional_Inf

RELATED PARTIES - Additional Information (Detail) (USD $)

1 Months Ended

12 Months Ended

1 Months Ended

0 Months Ended

12 Months Ended

Feb. 28, 2014

31-May-14

31-May-13

Oct. 11, 2013

Oct. 11, 2013

Feb. 01, 2012

Aug. 27, 2013

13-May-13

Jan. 18, 2013

Dec. 03, 2012

Oct. 01, 2012

Jun. 05, 2012

Feb. 01, 2012

31-May-14

Feb. 11, 2011

Nov. 11, 2009

Feb. 11, 2011

Nov. 11, 2009

31-May-13

31-May-14

Senior Secured Note

Senior Secured Note

Niobe Ventures LLC

Niobe Ventures LLC

Niobe Ventures LLC

Niobe Ventures LLC

Niobe Ventures LLC

Niobe Ventures LLC

Niobe Ventures LLC

Niobe Ventures LLC

Niobe Ventures LLC

Niobe Ventures LLC

Niobe Ventures LLC

Niobe Ventures LLC

Niobe Ventures LLC

Mr. Warshaw

Mr. Elser

Minimum

Senior Secured Note

Senior Secured Note

Senior Secured Note

Senior Secured Note

Senior Secured Note

Senior Secured Note

Senior Secured Note

Senior Secured Note

Senior Secured Note

Stock Purchase Agreement

Stock Purchase Agreement

Stock Purchase Agreement

Credit Facility Agreement

Senior Secured Note

Senior Secured Note

Related Party Transaction [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based compensation arrangement by share-based payment award, options, grants in period, gross

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

350,000

250,000

Weighted average exercise price of options

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1.05

$9

Share-based compensation arrangement by share-based payment award, award vesting rights

'

'Some of these options vested 50% upon issuance and the remainder vest on their one year anniversary. Some options vest ratably over 2 years while some vest upon the achievement of certain benchmarks.

'Some of these options vested 50% upon issuance and the remainder vest on their one year anniversary. Some options vest ratably over 2 years while some vest upon the achievement of certain benchmarks.

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'These options vested 50% upon issuance and the remainder will vest on May 22, 2014.

'These options vested 33.33% upon issuance, another 33.33% will vest on the 12 month anniversary of their issuance, and the remainder will vest on May 4, 2016.

Fair value of options

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$329,000

$2,018,000

Additional working capital raised

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,000,000

'

'

'

'

Common Stock issued, per share

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.23

'

'

'

'

Restricted shares of common stock issued, value

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,000,000

'

'

'

'

Senior secured convertible promissory note

'

'

'

'

'

'

2,000,000

'

'

'

'

'

'

'

2,000,000

'

1,000,000

1,000,000

'

'

Accrued interest on senior secured convertible promissory note

'

'

'

'

'

'

2,155,000

'

'

'

'

'

'

'

'

'

37,500

'

'

'

Senior secured convertible promissory note, conversion price per share

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.23

'

'

$0.23

'

'

Shares of common stock issuable upon conversion of senior secured convertible promissory note

'

'

'

'

'

'

'

'

'

'

'

'

'

'

8,695,652

'

4,510,870

'

'

'

Senior secured convertible promissory note, maturity date

'

'

'

1-Sep-15

'

1-Feb-14

27-Aug-15

13-May-15

15-Jan-15

1-Oct-14

1-Oct-14

31-May-14

1-Feb-14

'

31-Dec-12

'

'

'

'

'

Senior secured convertible promissory note, extended maturity date

'

'

'

'

'

'

'

'

'

'

'

'

'

'

31-Dec-13

'

'

'

'

'

Debt instrument, interest rate, effective percentage

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3.00%

'

'

'

'

'

Proceeds from secured notes payable

'

'

'

'

'

'

1,000,000

2,000,000

2,500,000

700,000

800,000

1,000,000

1,000,000

'

'

'

'

'

'

'

Debt instrument, face amount

'

'

'

9,000,000

'

'

1,000,000

2,000,000

2,500,000

700,000

800,000

1,000,000

1,000,000

9,000,000

'

'

'

'

'

'

Secured note payable, interest rate

'

'

'

3.00%

'

'

3.00%

3.00%

3.00%

3.00%

3.00%

3.00%

3.00%

'

'

'

'

'

'

'

Debt Conversion, Converted Instrument, Shares Issued

'

'

'

'

'

'

9,369,565

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt instrument carrying amount

'

'

'

9,219,366

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from Repayments of secured debt

'

'

'

7,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Terms of consolidated note identical to secured notes

'

'

'

'(a) the maturity date is September 1, 2015, which is after the latest maturity date of any of the Secured Notes; and (b) it provides for partial mandatory repayment in the event that the Company receives aggregate gross proceeds in excess of $7.5 million from a single or multiple “Liquidity Events” in an amount equal to twenty-five (25%) percent of such gross proceeds.

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Description of Liquidity Event

'

'

'

'(a) the sale of any of our equity, or equity-linked, securities, and (b) the receipt of proceeds, directly or indirectly related to a development and/or commercialization relationship entered into with an unaffiliated third party.

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Consummation of equity financing, amount

'

'

'

7,500,000

7,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Restricted shares of common stock issued

3,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

8,695,652

8,695,652

'

'

'

'

Share-based Compensation

'

$7,228,008

$906,977

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$164,500

$896,887

STOCK_OPTIONS_Additional_Infor

STOCK OPTIONS - Additional Information (Detail) (USD $)	12 Months Ended				12 Months Ended
	31-May-14	31-May-13	31-May-14	Oct. 25, 2005	31-May-14	31-May-13
			Stock Option Plan 2003	Stock Option Plan 2003	Stock Option	Stock Option
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]	'	'	'	'	'	'
Share based payment award number of shares authorized before amendment	'	'	'	300,000	'	'
Share based payment award number of shares authorized after amendment	'	'	'	900,000	'	'
Share-based payment award, shares issued in period	4,280,543	'	37,000	'	'	'
Share-based compensation arrangement by share-based payment award, options, exercises in period	'	'	800	'	'	'
Share-based compensation arrangement by share-based payment award, options, grants in period, gross	'	'	'	'	1,300,000	1,000,000
Shares authorized under stock option plans, exercise price range, lower range limit	'	'	'	'	$8.40	$1.05
Shares authorized under stock option plans, exercise price range, upper range limit	'	'	'	'	$9	$1.39
Stock granted, value, share-based compensation, gross	$9,385,000	$1,771,750	'	'	'	'
Allocated share-based compensation expense	5,789,996	735,667	'	'	'	'
Share-based compensation arrangement by share-based payment award, options, outstanding, number	'	'	4,317,543	'	'	'
Share-based compensation arrangement by share-based payment award, options, exercisable, number	'	'	3,350,876	'	'	'
Share-based compensation arrangement by share-based payment award, award vesting rights	'Some of these options vested 50% upon issuance and the remainder vest on their one year anniversary. Some options vest ratably over 2 years while some vest upon the achievement of certain benchmarks.	'Some of these options vested 50% upon issuance and the remainder vest on their one year anniversary. Some options vest ratably over 2 years while some vest upon the achievement of certain benchmarks.	'	'	'	'
share-based compensation arrangement by share-based payment award, options, outstanding, intrinsic value	20,782,678	20,782,678	'	'	'	'
Share-based compensation arrangement by share-based payment award, options, exercisable, intrinsic value	$351,821	$351,821	'	'	'	'
Share-based payment award, options, grants in period, weighted average remaining contractual term	'	'	'10 years	'	'	'

Summary_of_the_Common_Stock_Op

Summary of the Common Stock Option Activity for Employees, Directors, Officers and Consultants (Detail) (Stock Option, USD $)	12 Months Ended
	31-May-14	31-May-13	31-May-12	31-May-11
Stock Option	'	'	'	'
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]	'	'	'	'
Shares Outstanding at Beginning of Period	3,057,542	2,268,927	1,538,927	'
Shares Granted	1,300,000	1,000,000	750,000	'
Shares Exercised	0	0	0	'
Shares Forfeited	0	0	0	'
Shares Expired	-40,000	-211,385	-20,000	'
Shares Outstanding at End of Period	4,317,543	3,057,542	2,268,927	1,538,927
Shares Exercisable at May 31, 2014	3,350,876	'	'	'
Weighted AverageExercise Price, Outstanding at Beginning of Period	$1.09	$1.27	$1.99	'
Weighted AverageExercise Price, Granted	$8.51	$1.22	$1.01	'
Weighted AverageExercise Price, Exercised	$0	$0	$0	'
Weighted AverageExercise Price, Forfeited	$0	$0	$0	'
Weighted AverageExercise Price, Expired	$7.50	$7.52	$0	'
Weighted AverageExercise Price, Outstanding at End of Period	$3.26	$1.09	$1.27	$1.99
Weighted AverageExercise Price, Exercisable at May 31, 2014	$3.43	'	'	'
Expiry term of options	'6 years 8 months 1 day	'8 years 29 days	'7 years 7 months 24 days	'3 years 8 months 12 days
Weighted AverageRemaining ContractualTerm (Years), Granted	'5 years 9 months 29 days	'10 years	'10 years	'
Weighted AverageRemaining ContractualTerm (Years), Exercised	'0 years	'0 years	'0 years	'
Weighted AverageRemaining ContractualTerm (Years), Forfeited	'0 years	'0 years	'0 years	'
Weighted AverageRemaining ContractualTerm (Years), Expired	'0 years	'0 years	'0 years	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term	'7 years 9 months 29 days	'	'	'

Summary_of_the_Common_Stock_Op1

Summary of the Common Stock Option, by Exercise Price Range (Detail) (USD $)	12 Months Ended
	31-May-14
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Total Number	4,317,543
Total Weighted Average Exercise Price	$3.26
Total Weighted Average Remaining Life (years)	'6 years 8 months 1 day
Exercisable Number	3,350,876
Exercisable Weighted Average Exercise Price	$2.23
Exercisable, Weighted Average Remaining Life (years)	'6 years 7 months 6 days
Exercise Price Range One	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Exercise Price Range, Lower Range Limit	$0
Exercise Price Range, Upper Range Limit	$1
Total Number	1,230,543
Total Weighted Average Exercise Price	$0.44
Total Weighted Average Remaining Life (years)	'6 years 25 days
Exercisable Number	1,230,543
Exercisable Weighted Average Exercise Price	$0.44
Exercisable, Weighted Average Remaining Life (years)	'6 years 25 days
Exercise Price Range Two	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Exercise Price Range, Lower Range Limit	$1.01
Exercise Price Range, Upper Range Limit	$5
Total Number	1,750,000
Total Weighted Average Exercise Price	$1.13
Total Weighted Average Remaining Life (years)	'7 years 11 months 12 days
Exercisable Number	1,575,000
Exercisable Weighted Average Exercise Price	$1.32
Exercisable, Weighted Average Remaining Life (years)	'7 years 11 months 12 days
Exercise Price Range Three	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Exercise Price Range, Lower Range Limit	$5.01
Exercise Price Range, Upper Range Limit	$10
Total Number	1,300,000
Total Weighted Average Exercise Price	$8.51
Total Weighted Average Remaining Life (years)	'5 years 9 months 29 days
Exercisable Number	508,333
Exercisable Weighted Average Exercise Price	$8.51
Exercisable, Weighted Average Remaining Life (years)	'5 years 3 months
Exercise Price Range Four	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Exercise Price Range, Lower Range Limit	$10.01
Exercise Price Range, Upper Range Limit	$15
Total Number	37,000
Total Weighted Average Exercise Price	$13.86
Total Weighted Average Remaining Life (years)	'1 year 7 months 6 days
Exercisable Number	37,000
Exercisable Weighted Average Exercise Price	$13.86
Exercisable, Weighted Average Remaining Life (years)	'1 year 7 months 6 days

SENIOR_SECURED_NOTES_RELATED_P

SENIOR SECURED NOTES - RELATED PARTY - Additional Information (Detail) (USD $)	1 Months Ended
	Oct. 11, 2013	Oct. 11, 2013	Feb. 01, 2012	Aug. 27, 2013	13-May-13	Jan. 18, 2013	Dec. 03, 2012	Oct. 01, 2012	Jun. 05, 2012	Feb. 01, 2012	Aug. 31, 2013
	Senior Secured Notes	Senior Secured Notes	Niobe Ventures, LLC	Niobe Ventures, LLC	Niobe Ventures, LLC	Niobe Ventures, LLC	Niobe Ventures, LLC	Niobe Ventures, LLC	Niobe Ventures, LLC	Niobe Ventures, LLC	Niobe Ventures, LLC
		Minimum		Senior Secured Notes	Senior Secured Notes	Senior Secured Notes	Senior Secured Notes	Senior Secured Notes	Senior Secured Notes	Senior Secured Notes	Senior Secured Notes
Debt Instrument [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Proceeds from issuance of secured note	'	'	'	$1,000,000	$2,000,000	$2,500,000	$700,000	$800,000	$1,000,000	$1,000,000	'
Secured note payable	9,000,000	'	'	1,000,000	2,000,000	2,500,000	700,000	800,000	1,000,000	1,000,000	9,000,000
Secured note payable, interest rate	3.00%	'	'	3.00%	3.00%	3.00%	3.00%	3.00%	3.00%	3.00%	'
Secured note payable, maturity date	1-Sep-15	'	1-Feb-14	27-Aug-15	13-May-15	15-Jan-15	1-Oct-14	1-Oct-14	'	'	'
Debt instrument carrying amount	9,219,366	'	'	'	'	'	'	'	'	'	'
Proceeds from Repayments of secured debt	7,500,000	'	'	'	'	'	'	'	'	'	'
Terms of consolidated note identical to secured notes	'(a) the maturity date is September 1, 2015, which is after the latest maturity date of any of the Secured Notes; and (b) it provides for partial mandatory repayment in the event that the Company receives aggregate gross proceeds in excess of $7.5 million from a single or multiple Liquidity Events in an amount equal to twenty-five (25%) percent of such gross proceeds.	'	'	'	'	'	'	'	'	'	'
Description of liquidity event	'(a) the sale of any of the Companys equity, or equity-linked, securities, and (b) the receipt of proceeds, directly or indirectly related to a development and/or commercialization relationship entered into with an unaffiliated third party.	'	'	'	'	'	'	'	'	'	'
Consummation of equity financing, amount	'	$7,500,000	'	'	'	'	'	'	'	'	'

STOCKHOLDERS_EQUITY_Additional

STOCKHOLDERS EQUITY - Additional Information (Detail) (USD $)	1 Months Ended				1 Months Ended
	Feb. 28, 2014	31-May-14	31-May-13	Dec. 08, 2010	Jan. 23, 2014
					Private Placement
Stockholders' Equity Note Disclosure [Line Items]	'	'	'	'	'
Common Stock, Par or Stated Value Per Share	'	$0.00	$0.00	$0.00	'
Preferred Stock Shares Outstanding	'	0	0	1,000,000	'
Common Stock Of Accredited Investors Shares	3,000,000	'	'	'	471,334
Share Price	'	'	'	'	$6
Proceeds from Issuance of Private Placement	'	'	'	'	$2,828,000

SUBSEQUENT_EVENTS_Additional_I

SUBSEQUENT EVENTS - Additional Information (Detail) (USD $)	1 Months Ended
	Feb. 28, 2014	Jun. 30, 2014
		Subsequent Event
		Non Qualified Stock Option
Subsequent Event [Line Items]	'	'
Stock issued during period, shares, new issues	3,000,000	200,000
Share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price	'	$8.22
Expiry term of options	'	'5 years